Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews Sees Uptick in Q3 Revenues; Cuts Net Loss by 64 Percent

NEW YORK (GenomeWeb News) – Canadian biomarker test developer GeneNews reported today an uptick in third-quarter revenues to C$400,000 (US$382,000) from C$300,000 in the same quarter last year.

Toronto-based GeneNews attributed the revenue increase to an undisclosed collaborative research agreement; receipts from an Asian biomedical consortium; and sales of its lead product, the ColonSentry biomarker test for prognosing colon cancer risk.

GeneNews slashed its net loss by 64 percent to C$1.4 million from C$3.9 million year over year.

Meantime, the company cut its Q3 R&D expenses by 73 percent to C$700,000 from C$2.6 million in the year-ago period; lowered its sales and marketing expenses to $100,000 from $300,000; and reduced general and administrative expenses to C$500,000 from C$700,000.

GeneNews finished the quarter with cash and cash equivalents of C$1.3 million.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more